NervGen Pharma's Unattributed Round

NervGen Pharma raised a round of funding on September 20, 2018.

NervGen Pharma creates solutions for the treatment of nerve damage. NervGen's core technology focuses on the protein tyrosine phosphatase sigma (PTPĪƒ), a key neural receptor that inhibits nerve regen…

Articles about NervGen Pharma's Unattributed Round: